What Novitium Pharma does

Novitium Pharma is a US-based specialty pharmaceutical company founded in 2016 and headquartered in East Windsor, New Jersey, focused on the development, manufacturing, and distribution of niche generic pharmaceutical products. The company operates a state-of-the-art manufacturing facility at 70 Lake Drive, staffed by pharmaceutical scientists, engineers, and executives with over 50 years of combined experience. Its commercial portfolio spans multiple dosage forms and therapeutic categories, including Famotidine for Oral Suspension (generic Pepcid®), Fluphenazine Hydrochloride Tablets (generic Prolixin®), Sildenafil for Oral Suspension (generic Revatio®), and Thiothixene Capsules (generic Navane®), with all products manufactured domestically in the United States.

The company's go-to-market is B2B sales-led, targeting pharmacists as primary customers who in turn dispense to patients, with a horizontal segmentation approach across therapeutic categories rather than vertical specialization. Novitium has positioned itself in less competitive segments of the generics market — including antipsychotics, acid reduction, and pulmonary arterial hypertension — and has been identified as a key participant in the global Carglumic Acid market alongside Recordati Rare Diseases and Eton Pharmaceuticals. The value proposition emphasizes affordable prescription medicines, science-driven formulation, US-based quality control, and responsive execution in dynamic supply markets.

In 2021, Novitium was acquired by ANI Pharmaceuticals (NASDAQ: ANIP) and now operates as a wholly-owned subsidiary integrated into ANI's generics and CDMO operations. As a result, Novitium's product quality complaints and adverse event reporting channels have been consolidated under ANI ([email protected] and [email protected]), and the company's website explicitly identifies it as part of ANI Pharmaceuticals. The founders — Muthusamy Shanmugam, Chad Gassert (co-founder and CEO), and Vijay Thorappadi — continue to be associated with the business. No standalone revenue, funding rounds, patents, or AI/technology capabilities are disclosed in the available data.

Name

Novitium Pharma

Legal name

Novitium Pharma LLC

Website

https://novitiumpharma.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

51–100 employees

Short description

Novitium Pharma is a US-based niche generic pharmaceutical company founded in 2016, developing, manufacturing, and distributing affordable generic medications in oral suspension, tablet, and capsule forms. Acquired by ANI Pharmaceuticals in 2021, it serves pharmacists and patients across diverse therapeutic categories from its East Windsor, NJ facility.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Generic pharmaceuticals
• Niche generic medications
• Oral suspension formulations
• Prescription drug manufacturing
• US-based pharmaceutical manufacturing

Headquarters

HQ city

Windsor

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Products: Novitium generates revenue through the development, manufacturing, and distribution of niche generic pharmaceutical products. The company sells generic versions of brand medications across various dosage forms and therapeutic categories.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Novitium Pharma develops, manufactures, and distributes niche generic pharmaceutical products in dosage forms including oral suspensions, tablets, and capsules across various therapeutic categories. The company's products are manufactured at a state-of-the-art facility in East Windsor, New Jersey, and address formulations with limited competition in the generics market.

Product overview

Novitium Pharma is a U.S.-based pharmaceutical company specializing in development, manufacturing, and distribution of niche generic products. Founded in 2016, the company offers a portfolio of high-quality generic medications including oral suspensions (Famotidine, Sildenafil), tablets (Fluphenazine Hydrochloride), and capsules (Thiothixene). Novitium Pharma operates as part of ANI Pharmaceuticals following its acquisition and serves pharmacists and patients by providing affordable prescription options. The company's products span diverse therapeutic categories and dosage forms, all proudly manufactured in the USA at their state-of-the-art facility in East Windsor, New Jersey.

Differentiator

Problem solved

Functional benefit

Products and services

• Famotidine for Oral Suspension, USP Generic oral suspension formulation of Famotidine manufactured and distributed by Novitium Pharma.
• Fluphenazine Hydrochloride Tablets, USP Generic tablet formulation of Fluphenazine Hydrochloride manufactured and distributed by Novitium Pharma.
• Sildenafil for Oral Suspension Generic oral suspension formulation of Sildenafil manufactured and distributed by Novitium Pharma.
• Thiothixene Capsules, USP Generic capsule formulation of Thiothixene manufactured and distributed by Novitium Pharma.

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• ANI PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Novitium Pharma was acquired by ANI Pharmaceuticals in 2021. This acquisition significantly enhanced ANI's R&D capabilities and scale of generics and CDMO businesses. Novitium now operates as part of ANI Pharmaceuticals, with its website indicating Novitium is now part of ANI Pharmaceuticals.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Amneal Pharmaceuticals: Amneal Pharmaceuticals is a major US-based generic pharmaceutical manufacturer with a similarly diverse portfolio spanning multiple dosage forms and therapeutic categories. Both serve pharmacy channels with affordable generics and share manufacturing footprint overlap.
• Recordati Rare Diseases: Recordati Rare Diseases is identified alongside Novitium as a key Carglumic Acid competitor and operates in rare-disease and specialty pharmaceuticals. Direct overlap exists in niche/rare generic and specialty therapeutics.
• Lannett Company: Lannett Company is a US-based generic pharmaceutical manufacturer focused on oral solid, liquid, and topical dosage forms distributed through pharmacy channels. It directly overlaps with Novitium's generic portfolio approach and distribution model.
• Upsher-Smith Laboratories: Upsher-Smith Laboratories is a US-based generic and specialty pharmaceutical manufacturer producing tablets, capsules, and oral liquids. Its niche-focused generic strategy and US manufacturing footprint closely mirror Novitium's operating model.
• Eton Pharmaceuticals: Eton Pharmaceuticals is a niche specialty pharmaceutical company explicitly identified alongside Novitium as a key player in the Carglumic Acid market. Both companies target underserved therapeutic niches with small, focused product portfolios and similar business models.

Broad incumbents

• ANI Pharmaceuticals: ANI Pharmaceuticals (NASDAQ: ANIP) is the publicly-traded parent company that acquired Novitium in 2021. It operates a broader generics, specialty, and CDMO portfolio and shares overlap with Novitium across generic pharmaceuticals and contract manufacturing, making it the most directly comparable broad incumbent.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive operations in the US across tablets, capsules, and oral suspensions. It represents the broad incumbent competitive benchmark against which niche generic players like Novitium compete.
• Sandoz (Novartis): Sandoz is a global leader in generics and biosimilars with substantial US presence across all major dosage forms. Relevant broad incumbent for benchmarking Novitium's positioning in the US generic pharmaceutical market.
• Endo International: Endo International is a broad specialty and generic pharmaceutical manufacturer with significant US generic operations across multiple therapeutic categories. Comparable to Novitium as a larger incumbent in the US generics market.

Emerging players

• Woodward Pharma Services: Woodward Pharma Services is a smaller US-based specialty generic manufacturer focused on niche therapeutic categories with limited competition. It shares Novitium's niche-targeting strategy and sub-scale emerging-player profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novitium Pharma